atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917
Posted:
Atai Life Sciences a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, and its subsidiary GABA Therapeutics, announced final positive results from a Phase 1 clinical trial of GRX-917 that were previously announced as preliminary results during atai’s R&D day. Read more here.
RegTech Africa Conference is the premier gathering of regulators, innovators, ecosystem builders, investors, corporates, and other government representatives to engage, collaborate and share knowledge around new technologies and practices that support better regulations.
The three days hybrid conference which will…
It is free to use by the HCP community worldwide. In 2022 the library reached 25,000+ medical materials and the community exceeded 320,000+ professional subscribers (global audience). MEDtube is now the world's largest online repository with high-quality multimedia content of…
Attendees
Sponsors and Exhibitors
Media
Contact us